secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164435
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum shareholders reject stock plan amendment, approve officer liability limitation, elect directors
--------------------------------------------------------------------------------

- Stockholders did not approve amendment to 2019 Stock Incentive Plan: 23.7M for, 26.5M against, 48K abstain.
- Approved certificate amendment to limit officer liability under Delaware law: 49.0M for, 1.3M against, 16K abstain.
- Elected Alan Ezekowitz (41.3M for) and Sonja Banks (42.1M for) as Class I directors for three-year terms.
- Ratified Ernst & Young as independent auditor for FY2023: 53.6M for, 8K against, 380K abstain.
- Amendment to Restated Certificate filed with Delaware Secretary of State effective June 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523164435/0001193125-23-164435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523164435/d463131d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer